Walleye Capital
CHRS icon

Walleye Capital’s Coherus Oncology CHRS Stock Holding History

Walleye Capital’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-28,137
Closed -$48.7K – 5354
2024
Q2 		$48.7K Sell
28,137
-49,299
-64% -$99.2K ﹤0.01% 4934
2024
Q1 		$185K Sell
77,436
-22,619
-23% -$55.7K ﹤0.01% 4030
2023
Q4 		$333K Buy
100,055
+58,102
+138% +$156K ﹤0.01% 3288
2023
Q3 		$157K Buy
41,953
+21,299
+103% +$98.4K ﹤0.01% 3712
2023
Q2 		$88.2K Buy
+20,654
New +$122K ﹤0.01% 3478
2023
Q1 		– Sell
-16,467
Closed -$130K – 3970
2022
Q4 		$130K Buy
+16,467
New +$127K ﹤0.01% 2263

Other funds holding CHRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Walleye Capital's CHRS Position: Q3 2024 in Review

Walleye Capital sold out of Coherus Oncology (CHRS) in Q3 2024, closing a stake of 28,137 shares — an estimated $48.7K sold.

Walleye Capital first reported a position in CHRS in Q4 2022 and held it in 6 quarters. The position peaked at $333K in Q4 2023. 128 funds tracked by Wall St. Rank hold CHRS as of Q3 2024.

  • Walleye Capital reported no remaining Coherus Oncology position as of Q3 2024 after selling out during the quarter.
  • Walleye Capital sold 28,137 Coherus Oncology shares in Q3 2024, an estimated $48.7K.
  • Walleye Capital first reported a position in Coherus Oncology in Q4 2022 and held it in 6 quarters.
  • Walleye Capital's Coherus Oncology position peaked at $333K in Q4 2023.
  • 128 funds tracked by Wall St. Rank held Coherus Oncology as of Q3 2024.

Based on Walleye Capital's 13F filing for Q3 2024, filed 14 Nov 2024.